跳至主要内容
临床试验/NCT00741845
NCT00741845终止3 期

Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole

Embil Pharmaceutical Co. Ltd1 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2008年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
117
试验地点
1
主要终点
The specific aim of this study is to compare the rate of persistence of BV in non-pregnant women randomized to one of three different schemes of intravaginal metronidazole given nightly for 5 nights

研究概览

简要总结

This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women 18-40 yrs old
  • abnormal vaginal discharge or malodor
  • positive QuickVue test
  • positive KOH whiff test
  • Positive finding of clue cells greater than or equal to 20% on wet mount
  • Able to give informed consent
  • willing to abstain from alcohol during the 5 day therapy and 1 day following

排除标准

  • immunocompromised women
  • symptomatic VVC
  • pregnancy or positive pregnancy test
  • menstruating or breastfeeding women
  • other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks
  • women with MPC, PID

研究组 & 干预措施

1

Active Comparator

intravaginal metronidazole 750mg + 200mg miconazole

干预措施: intravaginal metronidazole (Drug)

2

Active Comparator

intravaginal metronidazole 750mg

干预措施: intravaginal metronidazole (Drug)

3

Active Comparator

intravaginal metronidazole 37.5mg

干预措施: intravaginal metronidazole (Drug)

结局指标

主要结局

The specific aim of this study is to compare the rate of persistence of BV in non-pregnant women randomized to one of three different schemes of intravaginal metronidazole given nightly for 5 nights

时间窗: 28 days after therapy initiation

次要结局

未报告次要终点

研究者

发起方
Embil Pharmaceutical Co. Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验